Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer
Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Responses in Lung Cancer
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma.
The name of the intervention(s) involved in this study are:
Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will include drugs already used as standard of care for the treatment of lung cancer and mesothelioma, or other drugs that are approved or being investigated for these indications.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This pilot research study is being conducted to evaluate the safety and feasibility of implanting and retrieving investigational drug-releasing microdevices in tumors of patients with lung cancer or malignant mesothelioma. The study will also explore the potential of these microdevices as a tool to assess how individual tumors respond to multiple anticancer drugs and drug combinations.
The microdevices are designed to release very small quantities (microdoses) of selected anticancer drugs directly into spatially distinct regions of a tumor. The drugs evaluated may include treatments currently approved for lung cancer or mesothelioma, as well as drugs approved for other cancer types that are being investigated as potential treatments for these diseases. The purpose of this localized drug exposure is to measure biological responses within the tumor tissue, rather than to provide therapeutic treatment.
The study involves implanting one or more microdevices, each small enough to fit within the tip of a needle, directly into an accessible tumor. The microdevices release microdoses of anticancer drugs through passive diffusion into the surrounding tumor tissue. Drug exposure is intended to remain localized to small regions of the tumor, with minimal systemic exposure.
After approximately 3 days, the microdevices and small regions of surrounding tumor tissue will be retrieved through a planned biopsy or surgical procedure. The collected tissues will be analyzed to evaluate local tumor responses to the individual drugs or drug combinations, including changes in tumor cell viability, cell death, and other biological markers of drug activity.
Research procedures may include screening for eligibility, clinical evaluations, imaging studies, microdevice implantation, tumor tissue sampling, blood collection, and follow-up visits.
The primary objectives of the study are to evaluate the safety and technical feasibility of microdevice implantation, localized drug delivery, and device retrieval in patients with lung cancer or mesothelioma. Exploratory objectives include characterizing tumor responses to multiple anticancer drugs and identifying biological markers associated with drug sensitivity or resistance.
The microdevice is investigational and has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of any disease. The microdevice-based drug testing procedure is experimental and is not intended to provide direct therapeutic benefit to participants.
Participation in this research study is expected to last up to 4 months.
Approximately 20 participants are expected to enroll, including 10 participants in each of two study cohorts.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Wczesna faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Raphael Bueno, MD
- Numer telefonu: 617-732-6824
- E-mail: rbueno@bwh.harvard.edu
Lokalizacje studiów
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Rekrutacyjny
- Brigham and Women's Hospital
-
Kontakt:
- Raphael Bueno, MD
- Numer telefonu: 617-732-6824
- E-mail: rbueno@bwh.harvard.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patients must have the ability to understand and the willingness to sign a written informed consent document.
-
Participants must have confirmed or suspected lung cancer or mesothelioma or other intrathoracic malignancy, and are planned for surgical resection of the tumor as part of their standard clinical care.
-
Participants must be 18 years of age or older.
-
Participants must be evaluated by a medical oncologist or surgeon who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease.
-
Patients must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures.
-
Participants will undergo laboratory testing within 30 days prior to the procedure (or within 72 hours if there has been a change in the clinical status since the initial blood draw). Patients must have absolute neutrophil count ≥1,000/mcL, platelets ≥120,000/mcL, Prothrombin time (PT) (International Normalized Ratio) 1.5 and Partial Thromboplastin Time (PTT) <1.5x control.
-
Participants must have undergone computed tomography (CT), magnetic resonance imaging (MRI)) or other clinical imaging that assesses the extent of disease and allows the research team to assess for study eligibility. This will have been done as part of the standard-of-care.
-
The participant's case must be reviewed by representatives of interventional radiology and the appropriate surgical subspecialty to assess the following factors:
- Patient is clinically stable to undergo microdevice implantation and surgical procedures.
- Patient has sufficient volume of disease to allow implantation of the microdevice.
- Patient has a lesion for which the microdevice is a) amenable to percutaneous placement, and b) amenable to removal at the time of surgery.
-
Patients must be willing to undergo research-related genetic sequencing (somatic and germline) and data management, including the deposition of de-identified genetic sequencing data in NIH central data repositories.
Exclusion Criteria:
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery.
- Uncorrectable bleeding or coagulation disorder known to cause increased risk with surgical or biopsy procedures (detailed below).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Implantable Microdevice (IMD) + Standard-of-care Surgical Retrieval + Standard-of-Care Treatment
Participants with confirmed or suspected lung cancer or malignant mesothelioma who are candidates for standard-of-care surgical tumor resection will be eligible for study participation and will undergo the following study procedures:
|
Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques. Drugs will include selected anticancer agents, such as methotrexate, gemcitabine, pemetrexed, paclitaxel, ipilimumab, nivolumab, pembrolizumab, carboplatin, abemaciclib, vinorelbine, etoposide, and osimertinib. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Safety of microdevice implantation and indwelling
Ramy czasowe: up to 30 days
|
Any grade 4-5 adverse events likely or definitely attributable to device placement, indwelling or retrieval Any death attributable to the study procedures and not attributable to the underlying malignancy or external causes Any device or microdose drug adverse effect resulting in major adverse events as defined in the protocol |
up to 30 days
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Feasibility of assessing tissue responses from microdevice treated tumor regions
Ramy czasowe: 14 days
|
Investigators will assess the technical feasibility of retrieving and processing the microdevices with surrounding tissue for downstream research analysis. A device retrieval is defined as successful if at least half of the reservoirs are surrounded by at least 500 microns of tissue. |
14 days
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Raphael Bueno, MD, Brigham and Women's Hospital
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Choroby płuc
- Nowotwory gruczołowe i nabłonkowe
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Gruczolak
- Nowotwory, mezotelium
- Rak, Bronchogenny
- Nowotwory oskrzeli
- Nowotwory płuc
- Międzybłoniak
- Rak, płuco niedrobnokomórkowe
- Rak Drobnokomórkowy Płuc
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 26-320
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Oliver Jonas, PhD. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Ramy czasowe udostępniania IPD
Data can be shared no earlier than 1 year following the date of publication.
Kryteria dostępu do udostępniania IPD
Contact the Partners Innovations team at http://www.partners.org/innovation.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .